Patients who are pregnant, nursing, or have certain conditions (such as pancreatitis, gallbladder disease, or thyroid cancer) may not be eligible
Exclusion criteria included the following: (1) alcohol consumption greater than 20 g/day
Dosing Schedules from Published Research Phase 2 Trial Dose Groups The Phase 2 clinical trial published in NEJM employed the following dose groups, all administered via subcutaneous injection once weekly: Scroll sideways to view the full table on mobile
While this is a real concern for the patient, the GPs decision is based on the established clinical effectiveness of the injection schedule
Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to peptide research relevant to KLOW Blend peptide components
Loved the service and will be back again